DS-1594b — Investigational Agent
Menin Inhibitor · Phase 1/2 · Daiichi Sankyo
Mechanism of Action
Orally administered small-molecule inhibitor of the menin–MLL (KMT2A) protein–protein interaction. Disrupting the menin–MLL complex downregulates leukemogenic HOXA9/MEIS1 transcriptional programs, inducing differentiation and apoptosis in KMT2A-rearranged and NPM1-mutated leukemias.
Investigational Indications
- Relapsed/refractory acute myeloid leukemia (KMT2A-rearranged or NPM1-mutated)
- Relapsed/refractory acute lymphoblastic leukemia
- Chronic myelomonocytic leukemia
- Myelodysplastic syndrome